<!doctype html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Pharmaceutical Innovation Clusters - ByteSized Research</title>

    <!-- Retro Font -->
    <link rel="preconnect" href="https://fonts.googleapis.com" />
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
    <link href="https://fonts.googleapis.com/css2?family=Press+Start+2P&display=swap" rel="stylesheet" />

    <link rel="stylesheet" href="css/styles.css" />

    <!-- Shared Styles & Components -->
    <link rel="stylesheet" href="/shared/styles/eject-button.css" />
    <script src="/shared/components/EjectButton.js"></script>
  </head>
  <body>
    <!-- EJECT BUTTON -->
    <eject-button></eject-button>

    <!-- Header -->
    <header class="header">
      <div class="container">
        <h1>Pharmaceutical Innovation Clusters</h1>
        <p class="subtitle">Discovering temporal patterns in FDA drug approvals</p>
      </div>
    </header>

    <!-- Main Content -->
    <main class="main-content">
      <div class="container">
        <!-- Introduction Section -->
        <section class="intro-section">
          <div class="intro-card">
            <h2>What Are Pharmaceutical Innovation Clusters?</h2>
            <p>
              History shows us that major pharmaceutical innovations don't happen randomly‚Äîthey cluster together in
              waves. Two-thirds of all antibiotic types ever discovered emerged in a single 20-year window
              (1940s-1960s). This analysis examines FDA drug approvals from 1939‚Äì2024 to identify these temporal
              patterns and reveal disparities in therapeutic development.
            </p>
          </div>
        </section>

        <!-- Statistics Section -->
        <section class="stats-section">
          <div class="stats-grid">
            <div class="stat-card">
              <div class="stat-number" id="total-innovations">---</div>
              <div class="stat-label">FDA Drug Approvals</div>
            </div>
            <div class="stat-card">
              <div class="stat-number" id="cluster-count">---</div>
              <div class="stat-label">Cluster Periods</div>
            </div>
            <div class="stat-card">
              <div class="stat-number" id="peak-decade">---</div>
              <div class="stat-label">Peak Decade</div>
            </div>
          </div>
        </section>
        <!-- Master Timeline Section -->
        <section class="timeline-section">
          <h2>üìä FDA Drug Approval Timeline</h2>
          <p class="section-description">
            Each bar represents a decade of pharmaceutical approvals. Hover to see exact counts.
          </p>
          <div
            id="master-timeline"
            class="timeline-container"
            role="img"
            aria-label="FDA drug approval timeline showing approvals by decade from 1939 to 2024"
          >
            <div class="loading">Loading timeline...</div>
          </div>
        </section>

        <!-- Statistical Analysis Section -->
        <section class="stats-tests-section">
          <h2>üî¨ Statistical Analysis Results</h2>
          <p class="section-description">
            Using the Coefficient of Variation and sliding window analysis, we can prove that pharmaceutical innovations
            cluster together rather than occurring randomly.
          </p>

          <div id="poisson-results" class="test-results-grid">
            <div class="loading">Loading statistical tests...</div>
          </div>
        </section>

        <!-- Drug Approval Clusters -->
        <section class="clusters-section">
          <h2>FDA Drug Approval Clusters</h2>
          <p class="section-description">
            Periods where drug approvals exceeded the historical mean by more than 1 standard deviation
          </p>
          <div id="fda-cluster-list" class="cluster-list">
            <div class="loading">Loading...</div>
          </div>
        </section>

        <!-- Pharmaceutical Insights Section -->
        <section class="unique-insights-section">
          <h2>üîç Pharmaceutical Insights</h2>
          <!-- Data Coverage Note -->
          <div
            style="
              margin: var(--spacing-md) auto;
              max-width: 900px;
              padding: var(--spacing-md);
              background: #fff3cd;
              border: 2px solid #ffc107;
              border-radius: var(--radius-pixel);
            "
          >
            <h4
              style="
                font-family: var(--font-pixel);
                font-size: 0.7rem;
                margin-bottom: var(--spacing-sm);
                color: var(--gb-dark);
              "
            >
              üìä Data Coverage Note
            </h4>
            <p style="font-size: 0.875rem; line-height: 1.6; margin: 0; color: var(--text-primary)">
              The therapeutic area analyses below are based on
              <strong>12,121 classified drugs (~17% of the 71,203 total FDA approvals)</strong>. Many older drugs
              (pre-1980s) lack complete pharmacological classification in FDA records. The patterns shown are
              representative of drugs with available therapeutic classifications, with classification accuracy improving
              significantly for post-2000 approvals.
            </p>
          </div>

          <!-- Temporal Clustering Pattern -->
          <div class="insight-container">
            <h3>üìä Temporal Clustering Patterns</h3>
            <p class="insight-intro">
              See when each therapeutic area had concentrated innovation "boom" periods. Each dot represents one drug
              approval.
            </p>
            <div
              id="therapeutic-timeline-container"
              role="region"
              aria-label="Temporal clustering patterns showing when each therapeutic area had concentrated innovation periods"
            >
              <div class="loading">Loading temporal clustering data...</div>
            </div>
          </div>

          <!-- Top Therapeutic Areas -->
          <div class="insight-container">
            <h3>Top Therapeutic Areas by Approval Count</h3>
            <p class="insight-intro">
              Broad therapeutic categories ranked by total FDA drug approvals. Shows which disease areas have attracted
              the most pharmaceutical investment.
            </p>
            <div id="top-therapeutic-areas">
              <div class="loading">Loading therapeutic areas data...</div>
            </div>
          </div>

          <!-- Emerging Drug Classes -->
          <div class="insight-container">
            <h3>Emerging Drug Classes (Only 1 Drug Each)</h3>
            <p class="insight-intro">
              Cutting-edge pharmaceutical innovations where only a single drug has been approved. These represent
              breakthrough therapies or novel mechanisms of action entering the market.
            </p>
            <div id="pharmaceutical-neglect">
              <div class="loading">Loading drug class data...</div>
            </div>
          </div>

          <!-- When Did Each Therapeutic Area Peak -->
          <div class="insight-container">
            <h3>When Did Each Therapeutic Area Peak?</h3>
            <p class="insight-intro">
              Discover which decades saw concentrated development for different therapeutic categories.
            </p>
            <div
              id="therapeutic-peaks-chart"
              role="img"
              aria-label="Chart showing which decades had peak drug approvals for different therapeutic categories"
            >
              <div class="loading">Loading peak analysis...</div>
            </div>
          </div>
        </section>

        <!-- The Generic Drug Revolution Section -->
        <section class="generic-revolution-section">
          <h2>The Generic Drug Revolution</h2>
          <p class="section-description">
            The 1980s saw the most drug approvals in history‚Äîbut was this pure innovation? Explore the shift from
            innovative drugs (new molecules) to generic drugs (bioequivalent copies).
          </p>
          <div
            id="decade-breakdown-chart"
            role="img"
            aria-label="Decade breakdown chart showing the shift from innovative drugs to generic drugs across decades"
          >
            <div class="loading">Loading decade breakdown data...</div>
          </div>

          <!-- Context Box -->
          <div
            style="
              margin-top: var(--spacing-md);
              padding: var(--spacing-md);
              background: #e8f5e9;
              border: 2px solid var(--gb-light);
              border-radius: var(--radius-pixel);
            "
          >
            <h4
              style="
                font-family: var(--font-pixel);
                font-size: 0.7rem;
                margin-bottom: var(--spacing-sm);
                color: var(--gb-dark);
              "
            >
              ‚ÑπÔ∏è Understanding Drug Types
            </h4>
            <ul
              style="font-size: 0.875rem; line-height: 1.6; margin: 0; padding-left: 1.5rem; color: var(--text-primary)"
            >
              <li>
                <strong>Innovative (NDA/BLA):</strong> New molecular entities, biologics, or novel combinations. These
                represent original pharmaceutical research.
              </li>
              <li>
                <strong>Generic (ANDA):</strong> Bioequivalent copies of off-patent drugs. Same active ingredient as the
                original but typically lower cost.
              </li>
              <li>
                <strong>Historical Context:</strong> The Hatch-Waxman Act (1984) created the modern generic drug
                approval pathway, eliminating the need for full clinical trials for bioequivalent drugs.
              </li>
              <li>
                <strong>Both are important:</strong> Generics improve access and affordability, while innovative drugs
                advance medical science.
              </li>
            </ul>
          </div>
        </section>

        <!-- Pharmaceutical Innovation Stories Section -->
        <section class="pharmaceutical-stories-section">
          <h2>üìö Pharmaceutical Innovation Stories</h2>
          <p class="section-description">
            Six data-driven insights revealing the breakthroughs, surges, and transformations in pharmaceutical
            development across decades.
          </p>
          <div id="pharmaceutical-stories">
            <div class="loading">Loading innovation stories...</div>
          </div>
        </section>

        <!-- Methodology Section -->
        <section class="methodology-section">
          <div class="container">
            <h2>Methodology</h2>
            <div class="methodology-grid">
              <div class="method-card">
                <h3>Data Sources</h3>
                <ul>
                  <li>FDA Orange Book API (drug approvals, 1939-2024)</li>
                  <li>71,149 total drug approvals analyzed</li>
                  <li>Classification via FDA pharmacological classes + indication fields</li>
                </ul>
              </div>
              <div class="method-card">
                <h3>Clustering Method</h3>
                <ul>
                  <li>Statistical threshold: >2œÉ above mean</li>
                  <li>Minimum cluster size: 3 consecutive years</li>
                  <li>Identifies periods of unusual approval density</li>
                </ul>
              </div>
            </div>
            <div class="disclaimer-card">
              <h3>Research Context</h3>
              <p>
                This analysis reveals temporal patterns in pharmaceutical innovation and therapeutic neglect but does
                not establish causality. Multiple factors‚Äîeconomic incentives, regulatory changes, disease prevalence,
                research funding, and market size‚Äîmay contribute to these patterns.
              </p>
            </div>
            <div class="disclaimer-card">
              <h3>Classification Methodology & Limitations</h3>
              <p><strong>Classification Approach:</strong></p>
              <ul style="margin-bottom: 15px">
                <li>
                  <strong>Data Source:</strong> FDA pharmacological class fields (EPC & MOA) with 345 unique classes
                </li>
                <li>
                  <strong>Simplification:</strong> Technical FDA terms converted to plain language (e.g., "Programmed
                  Death Receptor-1 Blocking Antibody" ‚Üí "PD-1 Inhibitors")
                </li>
                <li><strong>Secondary data:</strong> FDA indication and usage fields for context</li>
                <li>
                  <strong>Fallback:</strong> Keyword matching on generic drug names when FDA classification unavailable
                </li>
                <li>
                  <strong>No assumptions:</strong> Using actual FDA classifications, not manually-created therapeutic
                  buckets
                </li>
              </ul>
              <p><strong>Known Limitations:</strong></p>
              <ul>
                <li>
                  <strong>Combination drugs:</strong> Drugs with multiple therapeutic uses are assigned to a single
                  primary pharmacological class
                </li>
                <li>
                  <strong>Missing data:</strong> Older drugs (pre-1980s) may lack complete pharmacological
                  classification in FDA records (~86% unclassified)
                </li>
                <li>
                  <strong>Off-label use:</strong> Drugs approved for one condition but widely used for another are
                  classified by their FDA-approved indication only
                </li>
                <li>
                  <strong>Emerging categories:</strong> Gene therapies and novel modalities are classified under their
                  pharmacological mechanism, not disease
                </li>
                <li>
                  <strong>Data completeness:</strong> Classification accuracy improves for recent approvals (2000+) due
                  to more complete FDA metadata
                </li>
              </ul>
              <p style="margin-top: 15px">
                <em
                  >Note: Drug counts represent FDA-approved pharmacological classes, not therapeutic impact. Market
                  size, clinical significance, and innovation value may not correlate with approval counts. A class with
                  1 drug (e.g., "TYK2 Inhibitors") may represent groundbreaking innovation, while classes with 800+
                  drugs may be saturated markets.</em
                >
              </p>
            </div>
          </div>
        </section>
      </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
      <div class="container">
        <p>Data source: FDA Orange Book API (1939-2024)</p>
        <p>Analysis method: Statistical temporal clustering | Therapeutic area classification</p>
      </div>
    </footer>

    <!-- D3.js for interactive visualizations -->
    <script src="https://d3js.org/d3.v7.min.js"></script>

    <script src="js/app.js"></script>
    <script src="js/statistical-viz.js"></script>
    <script src="js/timeline-viz.js"></script>
    <script src="js/unique-insights.js"></script>
    <script src="js/therapeutic-peaks-viz.js"></script>
    <script src="js/decade-breakdown-viz.js"></script>
    <script src="js/therapeutic-timeline.js"></script>
  </body>
</html>
